Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
EXEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.14 - $40.02
Previous CloseN/A
Volume463.09K
Average Volume (3M)2.88M
Market Cap
$10.34B
Enterprise Value$6.57B
Total Cash (Recent Filing)$217.37M
Total Debt (Recent Filing)$190.82M
Price to Earnings (P/E)20.9
Beta0.26
Next Earnings
May 13, 2025EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.77
Shares Outstanding279,881,440
10 Day Avg. Volume3,108,445
30 Day Avg. Volume2,878,848
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)N/A
Price to Sales (P/S)4.77
Price to Cash Flow (P/CF)10.80
P/FCF Ratio10.80
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda9.14
Forecast
1Y Price Target
$37.81Price Target Upside2.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Exelixis News
PremiumCompany Announcements
Exelixis Earnings Call: Positive Growth and Ambitious Goals
---
Bulls Say, Bears Say
Bulls Say
EarningsExelixis recorded diluted net income that exceeded previous forecasts, indicating stronger-than-expected profitability.
Financial PositionExelixis ended the year with a substantial cash position of approximately $1.75 billion, providing financial stability and flexibility.
Pipeline DevelopmentThe early-stage pipeline remains on track, suggesting ongoing development and potential future growth.
Bears Say
Commercial RiskRisks include commercial risk regarding Cabometyx, failure to generate favorable clinical data, and the threat of generic erosion.
Forecast RiskLong-term Street forecasts for Zanza are $1-2bn vs EXEL guidance of around $5bn, possibly introducing risk asymmetry.
Market UncertaintyThe development path in the key renal cancer market likely remains a long-dated path to validation.
---
Ownership Overview
3.27% Insiders
24.98% Mutual Funds
25.76% Other Institutional Investors
18.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $20.14 and its highest was $40.02 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $10.34B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Feb 11, 2025. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.425 by $0.055.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.37.
How many shares outstanding does Exelixis have?
Exelixis has 279,881,440 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.48 in its last earnings report, beating expectations of $0.425. Following the earnings report the stock price went down -0.03%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
---
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.81 (2.30% Upside)
$37.81 (2.30% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 90%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 12.6%
Last 30 Days ▲ 12.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.51%
12-Months-Change
Fundamentals
Return on Equity
23.13%
Trailing 12-Months
Asset Growth
-0.31%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EXEL Company Deck
---
EXEL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Exelixis with strong growth in its cabozantinib franchise, significant regulatory and pipeline advancements, and a robust financial position. While there are challenges with increased operating expenses and gross to net deductions, the overall trajectory indicates momentum and growth opportunities.Read More>---
EXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
---
EXEL Stock 12 Month Forecast
Average Price Target
$37.81
▲(2.30% Upside)
Technical Analysis
Incyte
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
CytomX Therapeutics
―
Argenx Se
―
Best Analysts Covering EXEL
1 Year
1 Year Success Rate
22/25 ratings generated profit
1 Year Average Return
+24.57%
reiterated a buy rating 12 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 88.00% of your transactions generating a profit, with an average return of +24.57% per trade.
---